Santa Clarita-based Specialty Laboratories Inc.’s chief executive officer is stepping down to pursue other interests, the company announced Monday. The resignation comes a week after the laboratory’s chairman left the company’s board of directors.
Douglas S. Harrington, M.D., is set to leave his post March 29. Until then, he is scheduled to assist Specialty’s search for a new CEO.
“I believe the time is right for me to pursue my interest in other scientific and business ventures, and to spend more time with my family,” Harrington said in a statement. “In the interim, I look forward to working closely with the company’s leadership to ensure regulatory compliance, facilitate a smooth transition, and position Specialty for continued success.”
Kevin R. Sayer, Specialty’s chief financial officer, will be the company’s acting CEO upon Harrington’s departure.
Specialty Laboratories is a clinical laboratory for more than 10,000 hospitals and physicians in the United States.
Last week, Richard K. Whitney, a Specialty board member, was appointed chairman, replacing Richard E. Belluzzo, who resigned because of his responsibilities as CEO of Quantum Corp. Specialty’s board now consists of eight directors.
“Dr. Harrington’s leadership was a critical element of Specialty’s recent turnaround,” Whitney said in a statement. “Under his guidance, Specialty has significantly strengthened its business operations and emerged again as a premier provider of specialized clinical testing services to hospitals across the country. His strategic insight, clinical expertise and commitment to patient care have significantly transformed our organization.”
Last summer, Specialty began moving into its recently-constructed three-story 187,262-square-foot office, research and development and laboratory facility on 13.8 acres on Tourney Road.
The firm was formerly divided among four separate buildings in Santa Monica. The company said its facility in Santa Clarita allowed it to consolidate its operations into a single building and increase its available space for future growth and capacity.
“Today, Specialty is a stronger and more competitive company,” Harrington said. “Together, we built a unique and robust platform for long-term growth, restoring Specialty’s prestige as a service-focused and research-driven reference laboratory.”
Harrington has also stepped down as a member of Specialty’s board of directors, which now consist of seven directors.
On Monday, shares of Specialty Laboratories fell 39 cents, or 3.83 percent, to $9.80 on the New York Stock Exchange.
